Caterina Marchiò, MD, PhD, spiega perché l'implementazione del test CGP (Comprehensive Genomic Profiling) nel proprio istituto, rispetto all'invio dei campioni a un servizio esterno, può offrire maggiori opportunità ai pazienti di cancro nell'ambito della medicina di precisione. Caterina Marchiò, MD, PhD è professore di patologia presso l'Istituto Candiolo, Università di Torino, Italia. Convidi il video in inglese: https://youtu.be/NErI9YCGcn4 Learn about in-house CGP including homologous recombination deficiency (HRD): https://youtu.be/qz9auYRPvV8 Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM LinkedIn: https://www.linkedin.com/company/illumina X: https://x.com/illumina Instagram: https://www.instagram.com/illuminainc/ Facebook: https://www.facebook.com/illuminainc TikTok: https://www.tiktok.com/@illuminainc #CGP #MedicinadiPrecisione #Illumina